Symbio Pharmaceuticals Limited (4582) AI Stock Analysis

• Market Cap: ¥9.64B
• Dividend Yield: N/A
• Average Volume (3M): 577.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: -50.27%
• EPS Growth: -3.33%
• Country: JP
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -21.66
• Shares Outstanding: 59,567,080
• 10 Day Avg. Volume: 434,010
• 30 Day Avg. Volume: 577,100
• PEG Ratio: -0.08
• Price to Book (P/B): 3.55
• Price to Sales (P/S): 3.46
• P/FCF Ratio: -0.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ¥172.00 ▲(91.11% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held down primarily by weak financial performance (multi-year losses, heavy cash burn, and rising leverage), partially offset by strong technical momentum (price above key moving averages with positive MACD). Valuation is also a drag due to loss-making results (negative P/E) and no dividend yield data.

Positive Factors

High gross margin

A consistently strong gross margin indicates favorable product economics and pricing power in core drugs. That durable unit-level profitability can support recovery if operating costs are reined in, enabling efficient scaling of sales and targeted reinvestment into R&D or commercialization.

Specialty oncology/hematology focus

A focused specialty pharmaceutical franchise in oncology and hematology benefits from structural demand, high barriers to entry, and clinician stickiness. Specialty drugs often enjoy stable prescriber relationships and differentiated indications, underpinning long-term revenue potential despite near-term setbacks.

Licensing and collaboration model

A business model that generates licensing, milestone and royalty income diversifies revenue beyond direct sales and can provide non-dilutive funding. Strategic partnerships let the company leverage external commercialization resources, lowering fixed cost burden and risk while preserving upside from approved assets.

Negative Factors

Sustained revenue decline

Multi-year revenue erosion culminating in a steep 2025 decline suggests structural demand loss, portfolio shrinkage, or loss of commercial traction. Persistent top-line weakness undermines scale economics, reduces resources for R&D and commercialization, and raises the bar for any operational turnaround.

Material operating cash burn

Sustained negative operating and free cash flow across multiple years creates reliance on external financing and constrains strategic flexibility. Continued cash burn can force difficult choices—cutting investment, dilutive raise, or asset sales—unless operational loss trends reverse and cash generation restores.

Rising leverage and equity erosion

Leverage increasing from zero to meaningful debt while equity compresses raises fixed obligations and financial risk. With weak profits and cash generation, higher leverage limits ability to fund growth, increases refinancing risk, and elevates the chance of covenant pressure or dilutive capital raises.

Symbio Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

How the Company Makes Money

Symbio Pharmaceuticals Limited generates revenue through multiple streams, primarily by manufacturing and selling pharmaceutical products. The company's core revenue comes from the sale of its proprietary prescription drugs and over-the-counter medications to healthcare providers, pharmacies, and direct consumers. Symbio also engages in licensing agreements and strategic partnerships with other pharmaceutical companies, leveraging its research and development capabilities to co-develop new medications and treatments. Additionally, the company may receive milestone payments and royalties from these partnerships, further contributing to its income. By consistently investing in research and development, Symbio Pharmaceuticals ensures a steady pipeline of innovative products that drive its growth and profitability.

Symbio Pharmaceuticals Limited Financial Statement Overview

Summary

Financials are a major concern: revenue has declined for multiple years with a sharp drop in 2025, profitability swung to deeply negative operating and net margins in 2023–2025, and operating/free cash flow are meaningfully negative (cash burn). Added leverage in 2025 (debt rising above equity) and equity erosion further increase financial risk, despite a consistently strong gross margin.

Income Statement

Profitability has deteriorated materially after a strong 2021–2022 period. Revenue fell sharply in 2025 (down ~28% year over year) following declines in 2023–2024, and the company swung from solid positive margins in 2021–2022 to deeply negative operating and net margins in 2023–2025. While gross margin remains high, it has not translated into bottom-line profits, indicating a heavy cost burden outside of direct production (e.g., selling, R&D, or other operating costs).

Balance Sheet

The balance sheet shows increased financial risk versus prior years. Total debt rose to ~¥2.0B in 2025 after being zero in 2021–2024, pushing debt above equity (debt-to-equity ~1.56x). Equity has also compressed significantly from 2022–2024 levels, consistent with sustained losses, and returns on equity are sharply negative in 2023–2025. Offsetting this, the company still reports a meaningful asset base, but leverage and equity erosion reduce flexibility.

Cash Flow

Cash generation is a key weakness. Operating cash flow and free cash flow are meaningfully negative in 2023–2025, with an especially large cash burn in 2024–2025. The business is not funding itself from operations, and cash flow has moved in the same direction as earnings (loss-making years paired with cash outflows), raising reliance on external financing and heightening liquidity risk if losses persist.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.82B	1.31B	2.45B	5.59B	10.01B	8.25B
Gross Profit	1.37B	947.34M	1.87B	4.41B	7.60B	5.80B
EBITDA	-4.61B	-4.60B	-3.78B	-714.00M	2.06B	1.11B
Net Income	-4.66B	-4.78B	-3.83B	-1.96B	1.18B	2.03B
Balance Sheet
Total Assets	4.14B	3.87B	4.97B	8.17B	10.43B	8.45B
Cash, Cash Equivalents and Short-Term Investments	3.05B	2.88B	3.96B	6.52B	6.28B	3.86B
Total Debt	1.30B	1.98B	0.00	0.00	0.00	0.00
Total Liabilities	1.78B	2.60B	770.77M	960.33M	1.93B	1.71B
Stockholders Equity	2.36B	1.27B	4.20B	7.21B	8.51B	6.75B
Cash Flow
Free Cash Flow	0.00	-4.58B	-3.44B	-427.48M	1.57B	76.20M
Operating Cash Flow	0.00	-4.58B	-3.42B	-194.69M	1.61B	140.04M
Investing Cash Flow	0.00	-75.92M	-3.96M	-376.70M	-47.13M	-70.85M
Financing Cash Flow	0.00	3.62B	708.47M	680.16M	627.99M	-71.92M

Symbio Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 90.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Positive. The current price of 90 is below the 20-day moving average (MA) of 114.70, below the 50-day MA of 100.10, and below the 200-day MA of 133.16, indicating a bullish trend. The MACD of 23.09 indicates Negative momentum. The RSI at 69.01 is Neutral, neither overbought nor oversold. The STOCH value of 70.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4582.

Symbio Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4574	66 Neutral	¥15.83B	17.20	―	―	-5.41%	―
4539	64 Neutral	¥6.42B	11.77	―	3.21%	4.25%	―
4582	52 Neutral	¥9.64B	-1.70	―	―	-50.27%	-3.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4597	51 Neutral	¥10.10B	-9.94	-90.96%	―	243.16%	-23.00%
4512	48 Neutral	¥11.59B	38.82	―	1.06%	5.42%	-62.03%
4586	45 Neutral	¥6.29B	-5.96	―	―	-52.41%	-80.31%

Symbio Pharmaceuticals Limited Corporate Events

SymBio Pharmaceuticals’ Losses Deepen as Equity Thins Despite 2026 Sales Rebound Forecast

SymBio Pharmaceuticals reported a steep decline in consolidated net sales for fiscal 2025 to ¥1.31 billion, down 46.7% year-on-year, alongside widening operating and net losses, with profit attributable to owners of parent falling to a loss of ¥4.78 billion. The company’s financial position deteriorated markedly, with total assets shrinking, equity ratio plunging from 78.1% to 23.9%, and net assets per share dropping sharply, underscoring growing balance sheet pressure despite positive cash flow from financing activities and the continued suspension of dividends. For fiscal 2026, SymBio forecasts a near-tripling of net sales to ¥3.89 billion but still expects substantial operating and bottom-line losses, signaling that while revenue is projected to recover, profitability remains distant and capital structure risk will continue to be a key concern for investors and creditors.

The most recent analyst rating on (JP:4582) stock is a Sell with a Yen85.00 price target. To see the full list of analyst forecasts on Symbio Pharmaceuticals Limited stock, see the JP:4582 Stock Forecast page.